BioPharma Resources

Drug Trial Radar · NCT07342803

Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients

A Multicenter, Randomized, Double-Blind, Active Drug and Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in the Treatment of Patients With Moderate to Severe Persistent Allergic Asthma.

Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jan 25, 2025

Primary completion

Dec 28, 2027

Study completion Sep 30, 2029

Sponsor

Lead sponsor
Longbio PharmaIndustry
Sponsor type
Industry
First posted
Jan 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, masked, active and placebo controlled, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-003 injection in adult patients with moderate to severe persistent allergic asthma.

Conditions

  • Allergic Asthma

Interventions

  • LP-003 InjectionBiological

    s.c. injection, Q12W

  • OmalizumabBiological

    s.c. injection, Q4W

  • PlaceboBiological

    s.c. injection, Q4W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean number of asthma exacerbations per subjectTime frame: During the 24-week treatment period
  2. Proportion of subjects with asthma exacerbationsTime frame: During the 24-week treatment period
  3. Mean number of asthma exacerbations per subjectTime frame: During the 36-week and 48-week follow-up period
  4. Proportion of subjects with asthma exacerbationsTime frame: During the 36-week and 48-week follow-up period
  5. Proportion of subjects with loss of asthma control (LOAC) in each groupTime frame: During the 24-week treatment period
  6. Incidence of adverse events (AEs)Time frame: Up to approximately 52 weeks
  7. Change from baseline in pre-bronchodilator FEV1, FVC, and FEV1/FVC ratioTime frame: Weeks 4, 8, 12, 16, 20, and 24
  8. Change from baseline in weekly mean daily and weekly Peak Expiratory Flow (PEF) variability, and change from baseline in mean PEFTime frame: Weeks 4, 8, 12, 16, 20, and 24
  9. Time to first asthma exacerbation from baselineTime frame: Up to approximately 52 weeks
  10. Change from baseline in weekly use of reliever medication (Salbutamol Sulfate Aerosol)Time frame: Up to approximately 52 weeks
  11. Change from baseline in weekly Asthma Symptom Diary ScoreTime frame: Up to approximately 52 weeks
  12. Change from baseline in standardized Asthma Quality of Life Questionnaire (AQLQ(S))Time frame: Weeks 12 and 24
  13. Change from baseline in Asthma Control Questionnaire (ACQ-5)Time frame: Weeks 12 and 24
  14. Change from baseline in Asthma Control Test (ACT)Time frame: Weeks 12 and 24
  15. Change in serum free IgE levels over time at different time pointsTime frame: Up to approximately 52 weeks
  16. Serum concentrations of LP-003 at different time pointsTime frame: Up to approximately 52 weeks
  17. Incidence of Anti-drug Antibodies (ADA)Time frame: Up to approximately 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.